Michele Fiore1, Andrea Sambri2,3, Riccardo Zucchini4, Claudio Giannini4, Davide Maria Donati4,3, Massimiliano De Paolis2. 1. IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, 40136, Bologna, Italy. michele.fiore@ior.it. 2. Azienda ospedaliera Sant'Orsola Malpighi, Bologna, Italy. 3. Alma mater studiorum - University of Bologna, Bologna, Italy. 4. IRCCS Istituto Ortopedico Rizzoli, Via G.C. Pupilli 1, 40136, Bologna, Italy.
Abstract
AIM: Prosthetic joint infection (PJI) is a common complication following orthopedic megaprosthetic implantations (EPR), estimated up to 50%. Silver coatings were introduced in order to reduce the incidence of PJI, by using the antibacterial activity of silver. Three different silver coatings are available: MUTARS® (Implantcast), Agluna® (Accentus Medical), PorAg® (Waldemar Link). The aim of this review is to provide an overview on efficacy and safety of silver-coated EPR both in primary and revision surgery, comparing infection rate according to the type of implant. METHODS: Through an electronic systematic search, we reviewed the articles concerning silver-coated EPRs. Infection rate, silver-related complications, local and blood concentrations of the silver were evaluated. Meta-analyses were performed to compare results from each study included. RESULTS: Nineteen studies were included. The overall infection rate in patients with silver-coated implants was 17.6% (133/755). Overall infection rate in primary silver-coated EPR was been 9.2% (44/445), compared to 11.2% (57/507) of non-silver-coated implants. The overall infection rate after revisions was 13.7% (25/183) in patients with silver-coated EPR and 29.2% (47/161) when uncoated EPR were used, revealing a strength statistically significative utility of silver coatings in preventing infections in this group (p: 0.019). Generally, the use of MUTARS® EPR had produced an almost constant decrease in the incidence of primary PJI but there are few data on the effectiveness in revisions. The results from the use of Agluna® in both primary and revisions implants are inconstant. Conversely, PorAg® had proven to be effective both in PJI prevention but, especially, when used in PJI revision settings. Local argyria was reported in 8 out of 357 patients (2.2%), while no systemic complications were described. Local and blood concentrations of silver were always reported very far to the threshold of toxicity, with the lowest concentration found using PorAg®. CONCLUSIONS: Silver-coated EPRs are safe and effective in reduction in PJI and re-infection rate, in particular when used in higher risk patients and after two-stage revisions to fight PJI.
AIM: Prosthetic joint infection (PJI) is a common complication following orthopedic megaprosthetic implantations (EPR), estimated up to 50%. Silver coatings were introduced in order to reduce the incidence of PJI, by using the antibacterial activity of silver. Three different silver coatings are available: MUTARS® (Implantcast), Agluna® (Accentus Medical), PorAg® (Waldemar Link). The aim of this review is to provide an overview on efficacy and safety of silver-coated EPR both in primary and revision surgery, comparing infection rate according to the type of implant. METHODS: Through an electronic systematic search, we reviewed the articles concerning silver-coated EPRs. Infection rate, silver-related complications, local and blood concentrations of the silver were evaluated. Meta-analyses were performed to compare results from each study included. RESULTS: Nineteen studies were included. The overall infection rate in patients with silver-coated implants was 17.6% (133/755). Overall infection rate in primary silver-coated EPR was been 9.2% (44/445), compared to 11.2% (57/507) of non-silver-coated implants. The overall infection rate after revisions was 13.7% (25/183) in patients with silver-coated EPR and 29.2% (47/161) when uncoated EPR were used, revealing a strength statistically significative utility of silver coatings in preventing infections in this group (p: 0.019). Generally, the use of MUTARS® EPR had produced an almost constant decrease in the incidence of primary PJI but there are few data on the effectiveness in revisions. The results from the use of Agluna® in both primary and revisions implants are inconstant. Conversely, PorAg® had proven to be effective both in PJI prevention but, especially, when used in PJI revision settings. Local argyria was reported in 8 out of 357 patients (2.2%), while no systemic complications were described. Local and blood concentrations of silver were always reported very far to the threshold of toxicity, with the lowest concentration found using PorAg®. CONCLUSIONS:Silver-coated EPRs are safe and effective in reduction in PJI and re-infection rate, in particular when used in higher risk patients and after two-stage revisions to fight PJI.
Authors: Jendrik Hardes; Christof von Eiff; Arne Streitbuerger; Maurice Balke; Tymoteus Budny; Marcel P Henrichs; Gregor Hauschild; Helmut Ahrens Journal: J Surg Oncol Date: 2010-04-01 Impact factor: 3.454
Authors: Andrea Piccioli; Fabrizio Donati; Giulio Di Giacomo; Antonio Ziranu; Silvia Careri; Maria Silvia Spinelli; Silvana Giannini; Giuseppe Giannicola; Carlo Perisano; Giulio Maccauro Journal: Injury Date: 2016-08-25 Impact factor: 2.586
Authors: Chris P Wilding; George A Cooper; Alexandra K Freeman; Michael C Parry; Lee Jeys Journal: J Arthroplasty Date: 2016-04-22 Impact factor: 4.757
Authors: Jendrik Hardes; Helmut Ahrens; Carsten Gebert; Arne Streitbuerger; Horst Buerger; Michael Erren; Andreas Gunsel; Christian Wedemeyer; Guido Saxler; Winfried Winkelmann; Georg Gosheger Journal: Biomaterials Date: 2007-03-03 Impact factor: 12.479
Authors: Michael C Parry; Minna K Laitinen; Jose I Albergo; Czar L Gaston; Jonathan D Stevenson; Robert J Grimer; Lee M Jeys Journal: Eur J Surg Oncol Date: 2018-12-14 Impact factor: 4.424
Authors: Federico Sacchetti; Raphael Kilian; Francesco Muratori; Stephane Cherix; Lorenzo Foschi; Riccardo Morganti; Domenico Andrea Campanacci; Rodolfo Capanna Journal: Arch Bone Jt Surg Date: 2022-05
Authors: Vahid Zarghami; Mohammad Ghorbani; Kamran Pooshang Bagheri; Mohammad Ali Shokrgozar Journal: J Mater Sci Mater Med Date: 2022-05-21 Impact factor: 4.727